Introduction
CD8+ T cell response is a critical player for controlling HIV infection and AIDS progression. 1, 2 However, HIV-specific CD8+ T cells ultimately fail to control virus. Various mechanisms related either to HIV infected cells or to intrinsic defects in CD8+ T cells themselves have been proposed to explain this failure. [3] [4] [5] Among others, apoptosis of HIV-specific CD8+ T cells has been suggested as a strategy employed by HIV to evade the immune system. 6, 7 What governs this apoptosis-sensitivity, however, remains to be elucidated.
CD8+ T cells from HIV infected patients are susceptible to spontaneous and CD95/Fas-induced apoptosis. [8] [9] [10] We recently found HIV-specific CD8+ T cells to be highly sensitive to apoptosis 11 while this is not the case for CMV-specific CD8+ T cells from HIV+ individuals. 11 This sensitivity is associated with a remarkable downregulation of Bcl-2 and Bcl-xL anti-apoptotic molecules 12 suggesting a role of mitochondria in this apoptotic process. Several studies have revealed a mitochondrial dysfunction in T cells during HIV infection. 13, 14 CD95/Fas cross-linking initiates a complex signaling process involving CD95/Fas-capping and formation of Death Inducing Signaling Complex (DISC), 15, 16 ultimately leading to activation of the executor caspase-3 directly by caspase-8 or through mitochondrial secreted pro-apoptotic factors. 17 The cross-talk of these two pathways in apoptosis of primary T cells, particularly in CD8+ T cells from HIV+ patients, is currently unknown. Furthermore, no studies have addressed the role and impact of mitochondria in the apoptosis of HIV-specific CD8+ T cells.
HIV infection results in chronic activation of the immune system potentially contributing to T cell sensitization to apoptosis. 18, 19 Furthermore, HIV-specific CD8+ T cells were shown to be skewed toward a CD38+CD8+ phenotype while spontaneous and CD95/Fas-mediated apoptosis of CD38+CD8+
T cells was significantly higher in patients with high percentages of ex vivo CD38 expression on CD8+
For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From T cells. 6 These data raise the question whether chronic activation is the mechanism priming HIVspecific CD8+ T cells to apoptosis and whether CD38 expression is a predictive factor for this process.
In this study we have investigated the involvement of mitochondria in the apoptosis-sensitivity of HIV-specific CD8+ T cells. We present data describing an extensive mitochondrial network selectively found in HIV-specific CD8+ T cells. Furthermore, MM is independent of the maturation and activation level of HIV-specific CD8+ T cells while Bcl-2 expression is regulated by multiple factors in addition to chronic activation. Thus, proapoptotic HIV-specific CD8+ T cells are characterized by increased MM and reduced Bcl-2 levels on a background of chronic activation as determined by CD38
expression.
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Materials and methods

Donors. Peripheral blood was collected from HIV+ individuals (n= 40) following Drexel University
Institutional Review Board approval and obtaining informed consent. All individuals were HIV positive for at least 1 year (range: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , the median value of CD4 count was 468 cells/µl (range: 70-1178) and the viral load was 696 RNA copies/ml blood (range: <50-100,000), n=27 were asymptomatic and n=22
were on antiretroviral treatment. Control samples were obtained from HIV-negative age-matched healthy individuals (n=14).
Flow Cytometry. PBMC were freshly isolated by density centrifugation using Ficoll-Hypaque (Amersham Pharmacia Biotech, Sweden) from heparinized venous blood. Flow cytometry was performed as previously described. 11 HIV-and CMV-specific CD8+ T cells were identified using with HIV-Nef 71-80 (QVPLRPMTYK) peptide, as previously described. 20 The following antibody combinations were used: i) activation: anti-CD38-FITC/anti-CD8-PE-Cy5/HIV-or CMV-specific tetramer-APC ii) Bcl-2 and Bcl-x L expression: anti-CD38-FITC/anti-CD8-PE-Cy5/HIV-or CMVspecific tetramer-APC with Bcl-2-PE (BD Biosciences) or Bcl-x L -PE (Southern Biotechnology, Birmingham, AL) antibodies iii) apoptosis: anti-CD38-FITC/annexin V-PE/ anti-CD8-PE-Cy5/HIV-or CMV-specific tetramer-APC. Early and late apoptosis was analyzed using annexin V-Cy5. 5 
and Violet
Live/Dead Fixable Dead Cell Stain (Invitrogen, Carlsbad, CA) together with CD8-PE-Texas Red and
Gag-tetramer-APC after 6 hours culture in the presence or absence of plate bound anti-CD95 antibodies.
All monoclonal antibodies were purchased from eBioscience (San Diego, CA) unless otherwise indicated. Samples were collected on a FACS-Calibur and FACSAria (BD Biosciences, San Jose, CA)
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12
Apoptosis studies. Spontaneous, CD95/Fas-induced and treatment-specific apoptosis-sensitivity was determined by annexin V positivity as previously described.
11
Mitochondrial mass measurement. Incubation of PBMC with 100nM of MitoTracker® Green FM (Molecular Probes, OR, USA) for 45 min at 37ºC, 5% CO 2 , was followed by surface staining using the following antibody combinations: anti-CD8-PE/anti-CD38-PE-Cy5/HIV-or CMV-specific tetramer-APC, anti-CD8-PE-Texas Red/anti-CD45RA-Pacific Blue/anti-CD62L-PE-Cy7/HIV-or CMV-specific tetramer-APC or anti-CD8-PE/anti-CD45RA-PE-Cy5/anti-CD62L-APC. Fixation with 1% paraformaldehyde or incubation on ice has no effect on Mitotracker staining. Samples were collected immediately after the assay was completed. For acridine orange 10-nonyl bromide (nonyl acridine orange-NAO, Molecular Probes) staining, cells were first stained with anti-CD3-APC/anti-CD8-Pacific Blue/HIV-specific tetramer-APC, washed once and incubated with NAO (100nM) for 15min at 37ºC, 5% CO 2 . Unfixed samples were immediately collected on a FACS-Aria (BD) operated in BSL-3 facility.
Forward scatter (FSC) was used as a cell size index.
Confocal Microscopy studies. CD95/Fas-capping was induced in jurkat cells as previously described. 15 Briefly, 0.5x10 6 cells were incubated with CH-11 antibody (1µg/ml) for 1h in ice, transferred to 37 o C for 2 min (controls: no heat treatment) and transferred again on ice. After incubation with secondary Rhodamine Red -X-conjugated goat anti-mouse IgM antibody (Jackson Immunoresearch Laboratories, West Grove, PA) cells were transferred by cytospin onto poly-L-lysine coated slides (SIGMAFor personal use only. on April 16, 2017 . by guest www.bloodjournal.org From ALDRICH, MO, USA) and visualized using a confocal microscopy (Leica TCS SP2, Leica Microsystems, Heidelberg, GmbH) equipped with a 63/1.4 oil-immersion objective lens (Leica). For colocalization studies the Z-stack feature of the software was used to obtain a library of images of various sections of cells, 3D images were acquired using Leica Confocal Software (Leica Microsystems) and Adobe Photoshop 6.0 software (Adope Systems, San Jose, CA) was used to process them. A cell was considered as "capped" when the fluorescence condensed into less than 25% of the cell surface. 15 For studies with primary human CD8+ T cells, 1 x 10 6 positively purified CD8+ T cells (Dynal ASA, Oslo, Norway) were incubated with 5µg/ml of CH-11 antibody in 100 µl media for 1 h at 37 Laboratories, West Grove, PA)). To study HIV-specific CD8+ T cells, purified CD8+ T cells were first treated with anti-Fas antibody as above, stained with tetramer, fixed (1% PFA), sorted (FACS Aria, BD Biosciences) and transferred onto slides as above. The purity of sorted HIV-specific CD8+ T cells was >92%. To minimize the loss of cells, a second fixation step for 20 min with 4% PFA was performed.
CD95/Fas and porin co-staining was carried out as described above.
Statistical analysis. Statistical analysis was performed using Student's t-Test and regression analysis. Pvalues <0.05 were considered significant. The JMP statistical analysis program was used (SAS Institute
Inc., Cary, NC).
Results
HIV-specific CD8+ T cells express high MM
Here, we sought to examine the possible involvement of mitochondria in apoptosis of HIV-specific CD8+ T cells. As a first step, we measured ex vivo the MM of freshly isolated T lymphocytes from HIV+ patients and healthy donors. We used a mitochondrial-specific dye (MitoTracker® Green FM) 22, 23 that binds mitochondrial membrane independently of their membrane potential and thus staining intensity has been considered an index of their mass.
23-25
When gating on the CD8+ T cells two district populations can be observed; one exhibiting high MM and another with low MM ( Figure 1A ). The percentage of HIV-specific CD8+ T cells expressing high MM (77±7.2%, n=15) was found to be significantly higher compared to CMV-specific (50±5.9%, n=13, p=0.0001) and total CD8+ T cells from HIV+ patients (48.5±2%, n=40, p<0.0001) independently of the HIV-epitopes examined (A2-gag, A2-pol, A3-nef). This difference was even higher when HIVspecific CD8+ T cells were compared to total CD8+ T cells from healthy donors (21.5±6.7%, n=14, p<0.0001) ( Figure 1B) . Furthermore, our analysis revealed a greatly increased Mean Fluorescence Intensity (MFI) of MM, an index of the MM per cell, in HIV-specific CD8+ T cells (MFI=353±20) compared to CMV-specific (MFI=244±29, p<0.005) and total CD8+ T cells from HIV+ individuals (MFI=212±13, p<0.0001) and healthy donors ( Figure 1B ). It should be noted that similar data were obtained when the MM was examined only in patients that exhibited both HIV-and CMV-specific CD8+ T cells. Again, the percentages of HIV-specific CD8+ T cells expressing high MM (77±3%, n=10) was found to be significantly higher compared to CMV-specific CD8+ T cells (44±7.8%, n=8, p<0.001). Similarly, a significantly higher level of MM was observed in HIV-specific (MFI=343±29) compared to CMV-specific CD8+ T cells (MFI=209±33, p<0.01). By using the FSC as a cell size index, no difference was found between the low and high MM populations in all groups tested (data not figure 1) . HIV-specific CD8+ T cells however in this assay where not higher than total CD8+ T cells from HIV+ patients. This is most likely due to the reduced sensitivity and range the NAO stain on unfixed cells has compared to mitotracker. The standard NAO assay requires ethanol fixation which however cannot be combined with tetramer stains. Despite the limitations of using NAO on unfixed cells, these studies with NAO confirm our basic observation with mitotracker that HIV-specific CD8+ T cells have increased MM.
Our data revealed that an extensive mitochondrial network, potentially affecting their biology compared to other virus-specific CD8+ T cells from HIV+ patients, selectively characterizes HIV-specific CD8+ T cells. Figure 2B ). Such increased high mitochondrial mass was also found in early apoptotic cells after 6 hour anti-CD95 antibody treatment (supplementary figure 2). We found no difference in MM when early and late apoptotic Gag-specific and total CD8+ T cells were compared.
MM
Our data clearly demonstrate that increased MM is linked to apoptosis-sensitivity of CD8+ T cells from HIV+ patients.
MM is independent of the differentiation level of HIV-specific CD8+ T cells
Contrary to CMV-specific CD8+ T cells, HIV-specific CD8+ T cells exhibit a skewed maturation towards the preterminally differentiated (CD45RA-CCR7-CD62L-) effector memory compartment. 11, 26 Therefore, the observed differences in MM between the two virus-specific CD8+ T populations could be attributed, at least in part, to their different maturation level. We therefore directly investigated the levels of MM in relation to maturation status of virus-specific CD8+ T cells. and CD45RA+CD62L-(31.9±14.5%, n=5) subsets. Therefore differences of MM between HIV-specific and CMV-specific CD8+ T cells from HIV+ patients can not be attributed to difference in their maturation status.
MM does not correlate with CD38 expression on HIV-specific CD8+ T cells
Next, we attempted to investigate whether the MM of HIV-specific CD8+ T cells associates with their activation status (expression of the CD38 surface marker). A significantly increased percentage of CD38+ cells was found in HIV-specific (31.9±5.2%, n=10), CMV-specific (39.9±3.1%, n=17) and total CD8+ T cell populations (32.6±2.9%, n=35) from HIV+ patients compared to control CD8+ T cells (13±1.4%, n=14, p<0.007) ( Figure 4A ). This is in agreement with previously published data 6, 27 , including our own studies. 11 When the cell size was considered no difference was found between CD38+CD8+ and CD38-CD8+ T cells in all group tested (data not shown). MM was then measured in CD38+ and CD38-CD8+ T cell populations. Similar numbers of MM High CD8+ T cells was found to be expressed in both populations (89±2% vs 84±2.4%, n=4, 57±19% vs 44±18%, n=6, and 53±8% vs 44±10%, n=8 for CD38-and CD38+ HIV-, CMV-specific and total CD8+ T cells from HIV infected individuals respectively) ( Figure 4B ). Similarly, no difference was found when the percentage of CD38+CD8+ T cells was analyzed in the MM High and MM Low CD8+ T cells (data not shown).
Collectively, although our data reveal an increased activation status of virus-specific CD8+ T cells in HIV infection, the MM of these cells does not correlate with their activation status.
Expression of CD38 alone does not explain the selective apoptosis of HIV-specific CD8+ T cells
A significant correlation was observed between the ex vivo percentages of CD38+CD8+ T cells and spontaneous, CD95/Fas-induced and treatment-specific CD95/Fas-induced apoptosis of total CD8+T cells isolated from HIV+ patients ( Figure 5A ), in agreement with previously published data. 6 We further divided our population of HIV+ patients in low-CD38 and high-CD38 groups based on the median value of % CD8+ T cells expressing CD38 in all patients (median value 32%) as previously described. 6 These two groups presumably represent patients with low and high levels of chronic non-antigen specific activation respectively. Comparable spontaneous apoptosis was observed in both patient groups for HIV-and CMV-specific CD8+ T cells (data not shown). Similar levels of CD95/Fas-induced apoptosis was found in HIV-specific CD8+ T cells (37.6±5.9 vs 36.4±6.6% annexin V+ for high CD38, n=10, and low CD38 group, n=8, respectively) while higher CD95/Fas-induced apoptosis was found in CMVspecific CD8+ T cells from the high CD38 (n=11) (21.3±4.2% annexin V+) compared to the low CD38 group (n=11) (13.9±3.1% annexin V+). Comparison of both virus-specific CD8+ T cells revealed significantly higher CD95/Fas-induced apoptosis in HIV-compared to CMV-specific CD8+ T cells in both high CD38 and low CD38 group (p<0.004). When the apoptosis-sensitivity of CD38+ compared to
CD38-HIV-specific CD8+ T cells (
Figure 5B-C) was analyzed no difference was found in spontaneous apoptosis of CD38+ compared to CD38-HIV-specific CD8+ T cells ( Figure 5C ). In contrast, CD38+
HIV-specific CD8+ T cells exhibited significantly higher CD95/Fas-induced apoptosis (57.9±6%
annexin V+, n=6) compared to CD38-HIV-specific CD8+ T cells (37.2±6.6% annexin V+, p=0.04) and this was also true for specific CD95/Fas-induced apoptosis ( Figure 5C ). When CD38+ and CD38-CMV-specific CD8+ T cells were compared higher CD95/Fas-induced apoptosis-sensitivity was found ( Figure 5C ). Thus CD38 expression appears to confer increased apoptosis-sensitivity. However, spontaneous apoptosis was found to be moderately higher in CD38+ HIV-specific CD8+ T cells
For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From (16.8±5.3% annexin V+) compared to CD38+ CMV-specific (9.5±3% annexin V+) and total CD38+CD8+ T cells (11.5±1.7% annexin V+, n=15) from HIV+ patients ( Figure 5C ). This difference was found to be remarkably higher when the CD95/Fas-induced apoptosis was investigated. CD38+
HIV-specific CD8+ T cells were characterized by higher sensitivity (57.9±6% annexin V+) compared to CD38+ CMV-specific (30.4±7.7% annexin V+, p<0.02) and total CD38+CD8+ T cells (26.2±3.7%
annexin V+, p<0.0003) ( Figure 5C ). Finally, CD38-HIV-specific CD8+ T cells exhibit comparable levels of CD95/Fas-induced apoptosis (37.2±6.6% annexin V-, n=6) compared to CD38+ CMV-specific CD8+ T cells (30.4±7.7% annexin V+, n=7). Thus although CD38+ HIV-specific CD8+ T cells exhibit more apoptosis than CD38-HIV-specific CD8+ T cells, these later cells have comparable apoptosis to CD38+ CMV-specific CD8+ T cells. Therefore CD38 expression on virus-specific CD8+ T cells does not necessarily predict apoptosis-sensitivity. Our data indicate that in addition to CD38 expression, other factors also contribute to the selective sensitivity of HIV-specific CD8+ T cells to apoptosis.
Bcl-2 expression in HIV-specific CD8+ T cells is not solely dependent on their activation level
We examined the expression of the anti-apoptotic Bcl-2 and Bcl-x L molecules in relation to activation status of HIV-specific CD8+ T cells as these cells have markedly reduced levels of these molecules that may contribute to their apoptosis-sensitivity. 12 Expression of the activation marker CD38 was found to be associated with downregulation of Bcl-2 in all populations tested ( Figure 5D ). In CD38+ cells lower expression of Bcl-2 was found in HIV-specific (MFI=169±33, n=8, p<0.001), CMV-specific (MFI=264±26, n=13, p<0.01) and total CD8+ T cells (MFI=275±30, n=30, p<0.005) from HIV+ patients compared to CD8+ T cells from healthy donors (MFI=404±42, n=9) ( Figure 5D ). Bcl-2 levels were significantly lower in CD38+ HIV-specific compared to CD38+ CMV-specific CD8+ T cells from HIV+ individuals (p<0.04) ( Figure 5D ). In CD38-cells CMV-specific (MFI=432±35) and total CD8+ T cells (MFI=436±32) from HIV+ patients had Bcl-2 levels comparable to healthy CD8+ T cells (MFI=505±59). Bcl-2 expression, however, was considerably lower in CD38-HIV-specific CD8+ T cells (MFI=237±59) compared to CD38-CMV-specific (MFI=432±35, p<0.003) and total CD38-CD8+
T cells from HIV+ patients (MFI=436±32, p<0.007) and healthy donors (MFI=505±59, p<0.002) ( Figure 5D ). Analysis of the Bcl-xL expression revealed higher levels, although not statistically significant, of this molecule in CD38+ CMV-specific (MFI=70±10.7, n=4) compared to CD38+ HIVspecific CD8+ T cells (MFI=45±9.1, n=5). Therefore, Bcl-2 downregulation in HIV-specific CD8+ T cells may depend on activation as CD38+ cells have lower levels than CD38-cells, however these later cells still have lower levels than CD38+ CMV-specific CD8+ T cells suggesting that additional factors are involved in the regulation of Bcl-2 in HIV-specific CD8+ T cells.
CD95/Fas and mitochondria co-polarization in early steps of CD95/Fas-induced apoptosis of HIVspecific CD8+ T cells
The active involvement of mitochondria in apoptosis of HIV-specific CD8+ T cells has not been yet For
Discussion
We report here that HIV-specific CD8+ T cells are characterized by considerably increased MM when compared to other virus-specific cells such as CMV-specific CD8+ T cells from HIV+ individuals. We used a mitochondria-specific dye that binds mitochondrial membrane independently of their membrane potential and thus is considered as an index of their MM. [23] [24] [25] To the best of our knowledge, this is the first time to investigate this parameter in HIV-specific CD8+ T cells or primary human CD8+ T cells in 
to CMV-specific CD8+ T cells from HIV+ patients, and this correlates with their increased apoptosis-sensitivity. 11 Increased MM in HIV-specific CD8+ T cells compared to healthy CD8+ T cells was also found using NAO, a dye that binds cardiolipin and has been used as a marker of mitochondrial mass. 33 Contrary to mitotracker, no difference was observed between HIV-specific and total CD8+ T cells from HIV+ donors using NAO. This may be due to the reduced sensitivity and range of the NAO stain when performed on unfixed cells since the standard NAO assay requires ethanol fixation.
34,35
Unfortunately, ethanol fixation cannot be combined with tetramer stains. CD38 expression has been considered as a poor prognostic factor for HIV infected patients.
39,40
We found a strong correlation between ex vivo expression of CD38 and in vitro spontaneous as well as CD95/Fas-induced apoptosis of total CD8+ T cells from HIV infected patients. Analysis of virusspecific populations revealed that both HIV-and CMV-specific CD8+ T cells express high ex vivo percentages of CD38+ cells, in agreement with previous studies. 11, 27 Whether this represents a generalized, bystander activation of the immune system or a virus-specific activation is an open question. However, CMV-specific CD8+ T cells, even from patients expressing high ex vivo percentages of CD38+CD8+ T cells, were characterized by moderate apoptosis-sensitivity compared to
For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From HIV-specific CD8+ T cells, in agreement with our previous data. 11 Furthermore, our data revealed that indeed the presence of CD38 favors CD95/Fas-induced apoptosis, as indicated by the increased sensitivity of CD38+ compared to CD38-HIV-specific CD8+ T cells. The presence of CD38 had no effect in spontaneous apoptosis, implying a specific interaction between this surface molecule and CD95/Fas-induced signaling. CD38+ HIV-specific CD8+ T cells, however, are characterized by significantly higher apoptosis-sensitivity compared to CD38+ CMV-specific and total CD38+ CD8+ T cells from HIV+ patients, challenging a potentially principal role of CD38 in this process. In this case one should expect comparable sensitivity among the CD38+ CD8+ T cell populations tested irrespective of virus-specificity. Therefore, CD38 expression cannot explain on its own the selective apoptosissensitivity of HIV-compared to CMV-specific CD8+ T cells from HIV infected individuals. CD38+
HIV-specific CD8+ T cells exhibited dramatically lower ex vivo levels of the anti-apoptotic factor Bcl-2 compared to CD38+ CMV-specific CD8+ T cells, indicating an additional selective defect of HIVspecific CD8+ T cells. Surprisingly, CD38-HIV-specific CD8+ T cells also had significantly downregulated ex vivo Bcl-2 levels, and this was not observed in CD38-CMV-specific CD8+ T cells.
Thus CD38-HIV-specific CD8+ T cells have lower Bcl-2 and exhibit higher apoptosis compared to CD38-CMV-specific CD8+ T cells. These data indicate that although CD38 expression confers increased apoptosis-sensitivity to HIV-specific CD8+ T cells, it is not the sole factor controlling this death as CD38-HIV-specific CD8+ T cells also exhibit high apoptosis.
A critical issue in order to understand the molecular mechanism(s) governing the apoptosissensitivity of HIV-specific CD8+ T cells is whether the commitment to death takes place upstream or downstream of mitochondria, the main organelle where Bcl-2 family molecules exert their anti-apoptotic function. 41 To this end, the role of mitochondria in early steps of CD95/Fas-induced apoptosis of HIV-
specific and total CD8+ T cells from HIV+ individuals is unexplored. In vitro HIV studies based on
For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From ∆Ψm measurement may not be sufficient to definitely answer this question. A very early requisite step during CD95/Fas-induced apoptosis is the formation of CD95/Fas-capping. 16 Therefore, early molecular events can be monitored under CD95/Fas-capping experimental conditions. Special effort was undertaken to develop an assay allowing us to detect such a capping in HIV-specific CD8+ T cells.
Subsequently, a double-staining protocol was established for detection of mitochondrial localization, under capping conditions. Translocation-clustering of mitochondria upon death-receptor apoptosis induction has been previously described. Interestingly, the remarkable downregulation of Bcl-2 was also found to be independent of CD38 expression in HIV-specific CD8+ T cells. CD38 expression although a correlate of apoptosis-sensitivity does not explain on its own the selective apoptosis of HIV-specific CD8+ T cells. We therefore suggest that the combination of extensive MM with low expression of anti-apoptotic factors on an activated background selectively primes HIV-specific CD8+ T cells to apoptosis. Thus, mitochondria seem to be critical regulators of HIV-specific CD8 + T apoptosis as their colocalization with CD95/Fas aggregates also suggest. Therapeutic interventions targeting these organelles may be considered for strategies aiming at immune system reconstitution in HIV infection. The p values were calculated using Student's t test. 
